Please assess the completion status of the following clinical trial:

Trial Title: Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with NF1 will be selected for photodynamic therapy on the following criteria.~1. Age: 18 years or older.~2. NF1 will be diagnosed by American Academy of Neurology guidelines.~3. Location of tumor: cutaneous, trunk or limbs only.~4. Tumor type: superficial dermal neurofibromas, less than or equal to 4 mm deep.~5. Growth confirmation: direct measurement for the dermal neurofibromas, ruler and photo-volumetric method.~6. Informed consent of subject.~7. Absence of any other malignancy.~8. Only failures to meet criteria 1-6 due to the primary disease will be disqualifying~Exclusion Criteria:~Subjects will be excluded from participation in the study on the basis of the following:~1. Life expectancy less than 1 year.~2. Pregnancy.~3. Inability to consent.~4. Cutaneous photosensitivity to the wavelengths used to activate PDT.~5. A diagnosis of porphyria.~6. Allergy to aminolevulinic acid or any of the Topical Solution Vehicle components.~7. Previous chemotherapy within 6 weeks of proposed PDT.~8. Other concurrent tumor therapy. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 Levulan injection (Type: EXPERIMENTAL): 5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
- Part 1 Levulan painting (Type: EXPERIMENTAL): 5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
- Part 1 Levulan painted twice (Type: EXPERIMENTAL): 5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
- Part 1 Levulan painted twice with microneedling (Type: EXPERIMENTAL): 5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
- Part 2 Dose level 1 50 J/cm^2 (Type: EXPERIMENTAL): Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
- Part 2 Dose level 2 100 J/cm^2 (Type: EXPERIMENTAL): Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
- Part 2 Dose level 3 200 J/cm^2 (Type: EXPERIMENTAL): Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete